Protara Therapeutics, Inc. — Director's Dealing 2024

May 23, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2024-05-21

Reporting Person: Opaleye Management Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-21	Common Stock, par value $0.001 per share	S	31200	$3.0557	Disposed	2282159	Indirect
2024-05-21	Common Stock, par value $0.001 per share	S	1800	$3.0557	Disposed	124250	Indirect
2024-05-22	Common Stock, par value $0.001 per share	S	9300	$3.021	Disposed	2272859	Indirect
2024-05-22	Common Stock, par value $0.001 per share	S	500	$3.0021	Disposed	123750	Indirect

Footnotes

F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.

F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.

F3: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.01-$3.17 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.

F4: The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00-$3.03 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.